AUY922, a novel HSP90 inhibitor: Final results of a First-in-human study in patients with advanced solid malignancies.

被引：23
|
作者：
Samuel, T. A.
Sessa, C.
Britten, C.
Milligan, K. S.
Mita, M. M.
Banerji, U.
Pluard, T. J.
Stiegler, P.
Quad, C.
Shapiro, G.
机构：
[1] Med Coll Georgia, Augusta, GA 30912 USA
[2] Osped Reg Bellinzona & Valli, Oncol Inst Southern Switzerland, Bellinzona, Switzerland
[3] Univ Calif Los Angeles, Clin Res Unit, Los Angeles, CA USA
[4] Nevada Canc Inst, Las Vegas, NV USA
[5] Canc Therapy & Res Ctr S Texas, San Antonio, TX 78229 USA
[6] Royal Marsden Hosp, Drug Dev Unit, Sutton, Surrey, England
[7] Washington Univ, Sch Med, Div Med Oncol, St Louis, MO USA
[8] Novartis Pharmaceut, E Hanover, NJ USA
[9] Novartis Pharmaceut, Basel, Switzerland
[10] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.2528
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2528
引用
收藏
页数：1
相关论文
共 50 条
  • [31] First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors
    Shimomura, Akihiko
    Yamamoto, Noboru
    Kondol, Shunsuke
    Fujiwara, Yutaka
    Suzuki, Shigenobu
    Yanagitani, Noriko
    Horiike, Atsushi
    Kitazono, Satoru
    Ohyanagi, Fumiyoshi
    Doi, Toshihiko
    Kuboki, Yasutoshi
    Kawazoe, Akihito
    Shitara, Kohei
    Ohno, Izumi
    Banerji, Udai
    Sundar, Raghav
    Ohkubo, Shuichi
    Calleja, Elizabeth M.
    Nishio, Makoto
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (03) : 531 - 540
  • [32] Anticancer activity of Hsp90 inhibitor AUY922 in nasopharyngeal carcinoma and non-small cell lung cancer cells
    Cho, William C.
    Wong, Chi F.
    CANCER RESEARCH, 2023, 83 (07)
  • [33] The novel HSP90 inhibitor NVP-AUY922 demonstrates activity in rhabdomyosarcoma cell lines
    Slater, O.
    Renshaw, J.
    Workman, P.
    Pritchard-Jones, K.
    EJC SUPPLEMENTS, 2009, 7 (02): : 593 - 593
  • [34] Mechanistic Evaluation of the Novel HSP90 Inhibitor NVP-AUY922 in Adult and Pediatric Glioblastoma
    Gaspar, Nathalie
    Sharp, Swee Y.
    Eccles, Suzanne A.
    Gowan, Sharon
    Popov, Sergey
    Jones, Chris
    Pearson, Andrew
    Vassal, Gilles
    Workman, Paul
    MOLECULAR CANCER THERAPEUTICS, 2010, 9 (05) : 1219 - 1233
  • [35] RETRACTION: Potent antitumor activity of HSP90 inhibitor AUY922 in adrenocortical carcinoma (Retraction of Vol 35, Pg 8193, 2014)
    Huang, J.
    Sun, C.
    Zhang, T.
    TUMOR BIOLOGY, 2017,
  • [36] RETRACTED: Potent antitumor activity of HSP90 inhibitor AUY922 in adrenocortical carcinoma (Retracted article. See April, 2017)
    Huang, Junchao
    Sun, Chengchao
    Zhang, Ting
    Pan, Lei
    Wang, Suqing
    He, Qiqiang
    Li, Dejia
    TUMOR BIOLOGY, 2014, 35 (08) : 8193 - 8199
  • [37] Preclinical study of HSP-90 inhibitor drug, AUY922 showed good efficacy in treatment of nasopharyngeal cancer
    Yip, Timothy T. C.
    Ngan, Roger K. C.
    Ng, Wai-Tong
    Chan, Lewis T. C.
    Tai, William C. S.
    Cheng, Wai-Wai
    Ma, Victor W. S.
    Lo, Kwok-Wai
    Li, Ya-Ping
    Yang, Michael B. H.
    Wong, Eric C. H.
    Ma, Brigette B. Y.
    Mak, Nai-Ki
    Tsao, George S. W.
    Li-Lung, Maria
    CANCER RESEARCH, 2015, 75
  • [38] Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma
    T Stühmer
    A Zöllinger
    D Siegmund
    M Chatterjee
    E Grella
    S Knop
    M Kortüm
    C Unzicker
    M R Jensen
    C Quadt
    P Chène
    J Schoepfer
    C García-Echeverría
    H Einsele
    H Wajant
    R C Bargou
    Leukemia, 2008, 22 : 1604 - 1612
  • [39] NVP-AUY922:: A novel small molecule HSP90 inhibitor with potent in vivo antitumor efficacy
    Jensen, Michael Rugaard
    Schoepfer, Joseph
    Radimersky, Thomas
    Massey, Andrew
    Brueggen, Josef
    Schweitzer, Alain
    Pfaar, Ulrike
    Ruetz, Stephan
    Guy, Chantal
    Buckler, Alan
    Schnell, Christian
    Cozens, Robert
    Brough, Paul
    Drysdale, Martin
    Quadt, Cornelia
    Garcia-Echeverria, Carlos
    Chene, Patrick
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3521S - 3521S
  • [40] Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma
    Stuehmer, T.
    Zoellinger, A.
    Siegmund, D.
    Chatterjee, M.
    Grella, E.
    Knop, S.
    Kortuem, M.
    Unzicker, C.
    Jensen, M. R.
    Quadt, C.
    Chene, P.
    Schoepfer, J.
    Garcia-Echeverria, C.
    Einsele, H.
    Wajant, H.
    Bargou, R. C.
    LEUKEMIA, 2008, 22 (08) : 1604 - 1612
12345